Hansa Biopharma announces upcoming presentations including a late breaking poster presentation at the 2020 American Transplant Congress
Abstract highlights · 2-year follow-up data demonstrates graft survival of 90% for 31 patients post imlifidase treatment with a median eGFR of 61.5 ml/min. Despite varying levels of DSA rebound among these imlifidase-desensitized patients, the AMR frequency was comparable with those reported in other studies with less sensitized patients. · Reallocation of kidneys due to positive crossmatch affects the refused organ by increasing cold ischemia time and the eventual discard of kidneys. · Anti-HLA IgM antibodies are unaffected by imlifidase treatment.Lund May 20, 2020. Hansa